Nihal Bakeer

Nihal Bakeer

Auto-generated profile, based on publicly available information

Nihal Bakeer

Indiana Hemophilia and Thrombosis Center Indianapolis Indiana USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2022 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
JSJean St‐Louis
Jean St‐Louis
AAAudrey Abad
Audrey Abad
SFSharon Funk
Sharon Funk
MTMerlyn Tilak
Merlyn Tilak
SCStephen Classey
Stephen Classey
BFBrian Michael Feldman
Brian Michael Feldman
The Hemophilia Joint Health Score (HJHS) was developed and validated to detect arthropathy in children. Additional evidence is required to show validity in adults. We studied the convergent and discriminant construct validity of the HJHS version 2.1(HJHSv2.1) in adults with hemophilia. A secondary aim was to define age‐related normative adult HJHSv2.1 reference values. We studied 192 adults with hemophilia, and 120 healthy adults in four age‐matched groups—18 to 29, 30 to 40, 41 to 50, and >50 years—at nine centers. Trained physiotherapists scored the HJHS and World Federation of Hemophilia (WFH) joint score. Health history, the Functional Independence Scale of Hemophilia (FISH), Hemophilia Activities List (HAL), and Short‐Form McGill Pain Questionnaire (SF‐MPQ) were also collected. The median age was 35.0 years. Of participants with hemophilia, 68% had severe, 14% moderate, and 18% mild disease. The HJHS correlated strongly with WFH score (Spearman’s rho [rs ] = .95, P < .001). Moderate correlations were seen between the FISH (rs = .50, P < .001) and SF‐MPQ Present Pain Intensity (rs = .50, P < .001), while a modest correlation was found with the HAL (rs = −.37, P < .001). The HJHS significantly differentiated between age groups (Kruskal‐Wallis T = 35.02, P < .001) and disease severity in participants with hemophilia. The HJHS had high internal reliability (Cronbach’s α = .88). We identified duration of swelling as a redundant item in the HJHS. The HJHS shows evidence of strong convergent and discriminant construct validity to detect arthropathy in adults with hemophilia and is well suited for use in this population.

27 November 2020 in Haemophilia
Verified
Journal Article
Open access
PDF file
MLMagdalena Lewandowska
Magdalena Lewandowska
NRNicole Randall
Nicole Randall
NBNihal Bakeer
Nihal Bakeer
JMJennifer Maahs
Jennifer Maahs
JSJeanne Sagar
Jeanne Sagar
ASAmy D. Shapiro
Amy D. Shapiro
Introduction Surgery is frequently required in persons with haemophilia A (PwHA). Emicizumab, a bispecific, humanized monoclonal antibody, bridges activated factor (F) IX and FX. Management of patients undergoing surgery while receiving emicizumab is of clinical interest due to paucity of data. Aim Review real‐world experience of PwHA with/without FVIII inhibitors who required surgery while receiving emicizumab prophylaxis. Methods Data regarding peri‐operative management, including type of surgery, haemostatic agent use and bleeding complications, were collected for PwHA receiving emicizumab undergoing surgery between 25/10/18 and 31/12/19 at the Indiana Hemophilia and Thrombosis Center. Analyses were exploratory and descriptive. Results Twenty minor and five major surgeries were performed in 17 and five patients, respectively. Overall, 9/20 minor surgeries were planned to occur with emicizumab as the sole haemostatic agent; of these, four required additional coagulation factor (2 due to haematomas following port removals, 1 due to oozing at port removal site, 1 due to bleeding following squamous cell carcinoma removal). Three of the 11 minor surgeries with planned additional coagulation factor resulted in non‐major bleeds; all were safely managed with additional coagulation factor. All five major surgeries were planned with additional haemostatic agents; there was 1 bleed in a patient undergoing elbow synovectomy with nerve transposition, likely triggered by physical/occupational therapy. There were no major bleeds, thrombotic events or deaths. Conclusions Additional haemostatic agent use is safe in PwHA undergoing surgery while receiving emicizumab. Additional data are needed to determine the optimal dosing/length of treatment of additional haemostatic agents to lower bleeding risk.

10 July 2021 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
NBNihal Bakeer
Nihal Bakeer
SDSaunya Dover
Saunya Dover
PBPaul Babyn
Paul Babyn
BFBrian Michael Feldman
Brian Michael Feldman
ADAnnette von Drygalski
Annette von Drygalski
VBVictor S. Blanchette
Victor S. Blanchette
Introduction For persons with hemophilia, optimization of joint outcomes is an important unmet need. The aim of this initiative was to determine use of ultrasound in evaluating arthropathy in persons with hemophilia, and to move toward consensus among hemophilia care providers regarding the preferred ultrasound protocols for global adaptation. Methods A global survey of hemophilia treatment centers was conducted that focused on understanding how and why ultrasound was being used and endeavored to move toward consensus definitions of both point-of-care musculoskeletal ultrasound (POC-MSKUS) and full diagnostic ultrasound, terminology to describe structures being assessed by ultrasound, and how these assessments should be interpreted. Next, an in-person meeting of an international group of hemophilia health care professionals and patient representatives was held, with the objective of achieving consensus regarding the acquisition and interpretation of POC-MSKUS and full diagnostic ultrasound for use in the assessment of musculoskeletal (MSK) pathologies in persons with hemophilia. Results The recommendations were that clear definitions of the types of ultrasound examinations should be adopted and that a standardized ultrasound scoring/measurement system should be developed, tested, and implemented. The scoring/measurement system should be tiered to allow for a range of complexity yet maintain the ability for comparison across levels. Conclusion Ultrasound is an evolving technology increasingly used for the assessment of MSK outcomes in persons with hemophilia. As adoption increases globally for clinical care and research, it will become increasingly important to establish clear guidelines for image acquisition, interpretation, and reporting to ensure accuracy, consistency, and comparability across groups.

5 April 2024 in Haemophilia
Verified
Journal Article
Closed access
NBNihal Bakeer
Nihal Bakeer
WSWalid Saied
Walid Saied
AGAntonio Gavrilovski
Antonio Gavrilovski
CBCindy Bailey
Cindy Bailey

19 January 2023 in Pediatric Neurology
Verified
Journal Article
Closed access
SFSamantha J. Feldman
Samantha J. Feldman
LBLauren A Beslow
Lauren A Beslow
RFRyan Felling
Ryan Felling
LMLaura A. Malone
Laura A. Malone
MWMichaela Waak
Michaela Waak
LJLori C. Jordan
Lori C. Jordan

18 April 2024 in Haemophilia
Verified
Journal Article
Closed access
BLBjörn Lundin
Björn Lundin
NBNihal Bakeer
Nihal Bakeer
ADAmy L. Dunn
Amy L. Dunn
SGSridhar Gibikote
Sridhar Gibikote
SKShyamkumar N. Keshava
Shyamkumar N. Keshava
ADAndrea S. Doria
Andrea S. Doria